826 related articles for article (PubMed ID: 24687066)
1. Advances in targeting cyclic nucleotide phosphodiesterases.
Maurice DH; Ke H; Ahmad F; Wang Y; Chung J; Manganiello VC
Nat Rev Drug Discov; 2014 Apr; 13(4):290-314. PubMed ID: 24687066
[TBL] [Abstract][Full Text] [Related]
2. Structure-Based Discovery of PDEs Inhibitors.
Li L; Chen W; Chen T; Ren J; Xu Y
Curr Top Med Chem; 2016; 16(9):917-33. PubMed ID: 26303429
[TBL] [Abstract][Full Text] [Related]
3. Development of Phosphodiesterase-Protein-Kinase Complexes as Novel Targets for Discovery of Inhibitors with Enhanced Specificity.
Tulsian NK; Sin VJ; Koh HL; Anand GS
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34063491
[TBL] [Abstract][Full Text] [Related]
4. Clinical and molecular genetics of the phosphodiesterases (PDEs).
Azevedo MF; Faucz FR; Bimpaki E; Horvath A; Levy I; de Alexandre RB; Ahmad F; Manganiello V; Stratakis CA
Endocr Rev; 2014 Apr; 35(2):195-233. PubMed ID: 24311737
[TBL] [Abstract][Full Text] [Related]
5. Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets.
Ahmad F; Murata T; Shimizu K; Degerman E; Maurice D; Manganiello V
Oral Dis; 2015 Jan; 21(1):e25-50. PubMed ID: 25056711
[TBL] [Abstract][Full Text] [Related]
6. PDE2 at the crossway between cAMP and cGMP signalling in the heart.
Weber S; Zeller M; Guan K; Wunder F; Wagner M; El-Armouche A
Cell Signal; 2017 Oct; 38():76-84. PubMed ID: 28668721
[TBL] [Abstract][Full Text] [Related]
7. An update of cyclic nucleotide phosphodiesterase as a target for cardiac diseases.
Chen S; Yan C
Expert Opin Drug Discov; 2021 Feb; 16(2):183-196. PubMed ID: 32957823
[TBL] [Abstract][Full Text] [Related]
8. Cyclic nucleotide phosphodiesterase (PDE) inhibitors: novel therapeutic agents for progressive renal disease.
Cheng J; Grande JP
Exp Biol Med (Maywood); 2007 Jan; 232(1):38-51. PubMed ID: 17202584
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic potential of PDE modulation in treating heart disease.
Knight W; Yan C
Future Med Chem; 2013 Sep; 5(14):1607-20. PubMed ID: 24047267
[TBL] [Abstract][Full Text] [Related]
10. Modulation of Compartmentalised Cyclic Nucleotide Signalling via Local Inhibition of Phosphodiesterase Activity.
Brescia M; Zaccolo M
Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27706091
[TBL] [Abstract][Full Text] [Related]
11. Phosphodiesterase Inhibitors as a Therapeutic Approach to Neuroprotection and Repair.
Knott EP; Assi M; Rao SN; Ghosh M; Pearse DD
Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28338622
[TBL] [Abstract][Full Text] [Related]
12. Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments.
Keravis T; Lugnier C
Br J Pharmacol; 2012 Mar; 165(5):1288-305. PubMed ID: 22014080
[TBL] [Abstract][Full Text] [Related]
13. An update on cyclic nucleotide phosphodiesterase (PDE) inhibitors: phosphodiesterases and drug selectivity.
Gupta R; Kumar G; Kumar RS
Methods Find Exp Clin Pharmacol; 2005 Mar; 27(2):101-18. PubMed ID: 15834463
[TBL] [Abstract][Full Text] [Related]
14. Cyclic nucleotide phosphodiesterase 5 and sildenafil: promises realized.
Manganiello V
Mol Pharmacol; 2003 Jun; 63(6):1209-11. PubMed ID: 12761329
[No Abstract] [Full Text] [Related]
15. Cyclic nucleotide signalling compartmentation by PDEs in cultured vascular smooth muscle cells.
Zhang L; Bouadjel K; Manoury B; Vandecasteele G; Fischmeister R; Leblais V
Br J Pharmacol; 2019 Jun; 176(11):1780-1792. PubMed ID: 30825186
[TBL] [Abstract][Full Text] [Related]
16. Cardiac Cyclic Nucleotide Phosphodiesterases: Roles and Therapeutic Potential in Heart Failure.
Preedy MEJ
Cardiovasc Drugs Ther; 2020 Jun; 34(3):401-417. PubMed ID: 32172427
[TBL] [Abstract][Full Text] [Related]
17. Phosphodiesterase regulation of alcohol drinking in rodents.
Logrip ML
Alcohol; 2015 Dec; 49(8):795-802. PubMed ID: 26095589
[TBL] [Abstract][Full Text] [Related]
18. Targeting cyclic nucleotide phosphodiesterase in the heart: therapeutic implications.
Miller CL; Yan C
J Cardiovasc Transl Res; 2010 Oct; 3(5):507-15. PubMed ID: 20632220
[TBL] [Abstract][Full Text] [Related]
19. Role of phosphodiesterases III and IV in the modulation of vascular cyclic AMP content by the NO/cyclic GMP pathway.
Eckly AE; Lugnier C
Br J Pharmacol; 1994 Oct; 113(2):445-50. PubMed ID: 7834194
[TBL] [Abstract][Full Text] [Related]
20. Targeting Phosphodiesterases in Pharmacotherapy for Substance Dependence.
Wen RT; Liang JH; Zhang HT
Adv Neurobiol; 2017; 17():413-444. PubMed ID: 28956341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
